# EDGAR Filing Document

**Accession Number:** 0000711377
**File Stem:** 0001193125-26-148851
**Filing Date:** 2026-4
**Character Count:** 43852
**Document Hash:** e203935001884c29fa721e43ef180fb7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-148851.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0001193125-26-148851

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20260409

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEOGEN CORP
- **CENTRAL INDEX KEY:** 0000711377
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 382367843
- **STATE OF INCORPORATION:** MI
- **FISCAL YEAR END:** 0531

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17988
- **FILM NUMBER:** 26849789

**BUSINESS ADDRESS:**
- **STREET 1:** 620 LESHER PLACE
- **CITY:** LANSING
- **STATE:** MI
- **ZIP:** 48912
- **BUSINESS PHONE:** 5173729200

**MAIL ADDRESS:**
- **STREET 1:** 620 LESHER PLACE
- **CITY:** LANSING
- **STATE:** MI
- **ZIP:** 48912

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 OR 15(d)** 

**of The Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported)** **April 9, 2026**

------

NEOGEN CORPORATION

**(Exact name of registrant as specified in its charter)** 

------

---

| | | |
|:---|:---|:---|
| Michigan | 0-17988 | 38-2367843 |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| 620 Lesher Place Lansing**,** Michigan | 48912 |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code** 517**-**372-9200

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

---

| | | |
|:---|:---|:---|
| **Title of each Class**<br>| &nbsp;&nbsp;&nbsp;**Trading<br>Symbol(s)**<br>| &nbsp;&nbsp;&nbsp;**Name of each exchange<br>on which registered**<br>|
| Common Stock, $0.16 par value per share | NEOG | NASDAQ Global Select Market |

---

N/A

**(Former name or former address, if changed since last report.)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition** 

On April 9, 2026, Neogen Corporation issued a press release announcing results of operations for its fiscal 2026 third quarter ended February 28, 2026. A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.

**Item 9.01 Financial Statements and Exhibits** 

(d)Exhibits

---

| | |
|:---|:---|
| &nbsp;&nbsp;99.1 | [<u>Press Release dated April 9, 2026</u>](neog-ex99_1.htm) |
| &nbsp;&nbsp;104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | NEOGEN CORPORATION<br>|
|  | (Registrant) |
| Date: April 9, 2026 | /s/ R. Bryan Riggsbee<br>|
|  | R. Bryan Riggsbee |
|  | Chief Financial Officer |

---

------

## Exhibit 99.1

**Exhibit 99.1** 

**Neogen Reports Third Quarter Fiscal Year 2026 Financial Results**

• Fiscal third quarter 2026 revenue of $211.2 million

• Food Safety revenue growth of 2.6%, Core Growth<sup>1</sup> of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth<sup>1</sup> of (8.7%) due primarily to third-party supplier challenges in the quarter

• Net loss of $17.0 million in the third quarter 2026 with GAAP EPS of $(0.08), Adjusted Net Income of $19.4 million and Adjusted EPS of $0.09

• Third quarter 2026 cash flow from operations of $22.7 million and free cash flow of $11.1 million

• Adjusted EBITDA<sup>1</sup> of $48.2 million; Adjusted EBITDA margins<sup>1</sup> of 22.8% increases sequentially by 110 basis points

• Petrifilm<sup>®</sup> manufacturing transition remains on track for November FY27; Company has initiated operational and performance validation on multiple single kit units (SKUs)

• Divestiture of Genomics business unit announced and anticipated to close in 2Q27; Net cash proceeds support net debt-to-adjusted EBITDA<sup>1</sup> of less than three times by end of CY2026

• Raising fiscal year 2026 revenue outlook and maintaining Adjusted EBITDA guidance

<sup>1</sup>Non-GAAP financial measures; see explanations and reconciliations that follow

LANSING, April 9, 2026 – Neogen<sup>®</sup> Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced its financial results for the fiscal third quarter of 2026 and provided updated full fiscal year 2026 financial guidance.

"We continued to make significant progress on our strategic transformation in the third quarter as we look to stabilize and strengthen our core business. We are emboldened by the continued strength in core growth in our Food Safety segment. Combined with our major strategic sales initiatives such as our go-to-market strategy review, our increasing use of metric-based key performance indicators, and our transition to a standardized global solutions based selling approach, we believe we are well positioned for continued fundamental improvement across the organization," said Mike Nassif, Neogen's Chief Executive Officer and President.

He continued, "In the third quarter our Animal Safety business suffered several third-party, supply-based, setbacks leading to lower-than-anticipated growth, and we are actively engaged in improving these production-related challenges through our supplier qualification and sales and operations planning process. Despite these transient issues, we were able to deliver strong adjusted EBITDA through solid cost control and we continue to see opportunities to drive efficiency through technology and process across the company. We are confident that we will emerge from this fiscal year stronger and more capable as an organization, and increasingly focused on building upon our market leading position in Food Safety through discipline, improved enterprise capabilities, a renewed focus on innovation leadership, and a dramatically improved selling process."

------

**Financial Highlights**

**Revenue by Products and Geography**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended February 28,** | **Three months ended February 28,** |  | **Nine months ended February 28,** | **Nine months ended February 28,** |  |
|  | **2026** | **2025** | **Change %** | **2026** | **2025** | **Change %** |
| **<u>Food Safety</u>** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Natural Toxins & Allergens | $17.9 | $17.6 | 1.7% | $58.3 | $58.5 | (0.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Bacterial & General Sanitation | 42.1 | 39.9 | 5.5% | 128.7 | 122.3 | 5.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Indicator Testing & Culture Media | 83.0 | 74.8 | 11.0% | 245.9 | 232.9 | 5.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;Biosecurity Products | 3.9 | 11.8 | (66.9)% | 14.3 | 35.7 | (59.9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Genomics Services | 6.2 | 5.7 | 8.8% | 18.0 | 17.1 | 5.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 3.6 | 3.0 | 20.0% | 9.1 | 9.8 | (7.1)% |
| &nbsp;&nbsp;Total Food Safety Revenue | $156.7 | $152.8 | 2.6% | $474.3 | $476.3 | (0.4)% |
| **<u>Animal Safety</u>** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Life Sciences | $1.5 | $1.5 |  | $4.8 | $4.9 | (2.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Veterinary Instruments & Disposables | 15.5 | 15.5 |  | 41.1 | 45.4 | (9.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Animal Care & Other | 5.9 | 10.4 | (43.3)% | 22.3 | 26.7 | (16.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Biosecurity Products | 15.0 | 23.8 | (37.0)% | 52.2 | 66.6 | (21.6)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Genomics Services | 16.6 | 17.0 | (2.4)% | 50.4 | 49.3 | 2.2% |
| &nbsp;&nbsp;Total Animal Safety Revenue | $54.5 | $68.2 | (20.1)% | $170.8 | $192.9 | (11.5)% |
| **Total Revenues** | $211.2 | $221.0 | (4.4)% | $645.1 | $669.2 | (3.6)% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended February 28,** | **Three months ended February 28,** |  | **Nine months ended February 28,** | **Nine months ended February 28,** |  |
|  | **2026** | **2025** | **Change %** | **2026** | **2025** | **Change %** |
| Domestic | $102.3 | $115.4 | (11.4)% | $314.8 | $333.5 | (5.6)% |
| International | 108.9 | 105.6 | 3.1% | 330.3 | 335.7 | (1.6)% |
| Total revenue | $211.2 | $221.0 | (4.4)% | $645.1 | $669.2 | (3.6)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Revenues for the third quarter were $211.2 million, a decrease of 4.4% when compared to $221.0 million in the prior year. Core revenue, which excludes the impacts of foreign currency translation, as well as divestitures completed and product lines discontinued in the last 12 months, increased by 0.1%.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Food Safety segment revenue was $156.7 million in the third quarter, increasing 2.6% relative to the third quarter of fiscal year 2025. Core Food Safety revenue increased 4.0% on a year-over-year basis. The company saw especially strong growth in the quarter from indicators and culture media which was up 11.0% and from bacterial and general sanitation which was up 5.5%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Animal Safety segment revenue was $54.5 million in the third quarter, decreasing 20.1% relative to the third quarter of fiscal year 2025. Core Animal Safety revenue decreased (8.7%) on a year-over-year basis. The company experienced a number of third-party supplier issues in the quarter, which negatively impacted revenue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Domestic revenue in the quarter was $102.3 million and international revenue was $108.9 million. The company saw strong growth in Europe and Latin America, and U.S growth was negatively impacted by the Animal Safety supplier challenges given sales of these products predominately occur in the U.S.

**Summary of Income Statement** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended February 28,** | **Three months ended February 28,** | **Nine months ended February 28,** | **Nine months ended February 28,** |
|  | **2026** | **2025** | **2026** | **2025** |
| Revenue | $211.2 | $221.0 | $645.1 | $669.2 |
| Cost of revenues | 112.2 | 110.7 | 344.4 | 340.7 |
| Gross profit | 99.0 | 110.3 | 300.7 | 328.5 |
| &nbsp;&nbsp;Gross Margin | 46.9% | 49.9% | 46.6% | 49.1% |
| Operating expenses | 102.3 | 104.9 | 325.4 | 778.3 |
| Operating loss (income) | $(3.3) | $5.4 | $(24.7) | $(449.8) |
| &nbsp;&nbsp;Operating Margin | (1.6)% | 2.4% | (3.8)% | (67.2)% |
| EBITDA | $22.5 | $36.7 | $133.7 | $(360.7) |
| &nbsp;&nbsp;EBITDA Margin | 10.7% | 16.6% | 20.7% | (53.9)% |
| Net (Loss) Income | $(17.0) | $(10.9) | $3.4 | $(479.8) |
| &nbsp;&nbsp;Net (Loss) Earnings Per Diluted Share | $(0.08) | $(0.05) | $0.02 | $(2.21) |
| Adjusted Gross Profit | $109.2 | $113.5 | $325.9 | $344.7 |
| &nbsp;&nbsp;Adjusted Gross Margin | 51.7% | 51.4% | 50.5% | 51.5% |
| Adjusted Operating Income | $42.2 | $42.6 | $114.8 | $126.1 |
| &nbsp;&nbsp;Adjusted Operating Margin | 20.0% | 19.3% | 17.8% | 18.8% |
| Adjusted EBITDA | $48.2 | $48.6 | $132.4 | $143.6 |
| &nbsp;&nbsp;Adjusted EBITDA Margin | 22.8% | 22.0% | 20.5% | 21.5% |
| Adjusted Net Income | $19.4 | $20.9 | $51.5 | $59.6 |
| &nbsp;&nbsp;Adjusted Earnings Per Share | $0.09 | $0.10 | $0.24 | $0.27 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Gross margin was 46.9% in the third quarter of fiscal 2026. This compares to a gross margin of 49.9% in the same quarter a year ago, with the decrease primarily due to duplicative costs related to the company's Petrifilm manufacturing transition with some impact from tariff costs and inventory write-offs. Excluding integration-related costs, third quarter Adjusted Gross Margin<sup>1</sup> was 51.7% compared to 51.4% in the prior-year quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Net loss for the third quarter was $17.0 million, or $(0.08) per diluted share, compared to a net loss of $10.9 million, or $(0.05) per diluted share, in the prior-year period. Adjusted Net Income for the third quarter was $19.4 million, or $0.09 per diluted share, compared to $20.9 million, or $0.10 per diluted share, in the prior-year period.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Third-quarter Adjusted EBITDA was $48.2 million, representing an Adjusted EBITDA Margin of 22.8%, compared to $48.6 million and a margin of 22.0% in the prior-year period. The higher adjusted EBITDA Margin was the result predominantly of cost saving initiatives implemented at the end of the first quarter of fiscal year 2027 leading to lower operating expense spend.

**Business and Operational Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Neogen is currently completing a review of its global go-to-market strategy. As part of this review, the company plans to realign resources to higher-return markets, establish unified solutions-based selling standards for all global markets, and enhancing performance rigor through metric-based analysis under new commercial leadership

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Neogen advanced the transition to its new Petrifilm<sup>®</sup> manufacturing line. The company has completed validation on 100% of Petrifilm equipment and is actively engaged in both operational and performance validation of multiple SKUs. The company remains on track with previous timelines to have its manufacturing transition completed by November 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Neogen announced that it has entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. for a purchase price of $160.0 million, subject to customary closing adjustments. The deal is expected to close by the end of the company's second quarter of fiscal year 2027. Net proceeds from the transaction after closing costs and taxes are anticipated to be approximately $140.0 million.

**Financial Guidance**

---

| | | | |
|:---|:---|:---|:---|
| ***(in millions)*** | **Updated FY26 Guidance** | **Previous FY26 Guidance** | **Increase at Midpoint** |
| Revenue | $857 - $860 | $845 - $855 | $8.5 |
| Adjusted EBITDA<sup>1</sup> | Approximately $175 | Approximately $175 | $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The company is increasing its fiscal year 2026 revenue guidance and is now calling for revenue of $857 million to $860 million and is maintaining its adjusted EBITDA guidance of approximately $175 million. This compares with previous revenue guidance which called for revenue of $845 million to $855 million.

Adjusted EBITDA is a non-GAAP measure. The Company is not able to reconcile the Adjusted EBITDA outlook to the most directly comparable GAAP measure, forecasted net income, on a forward-looking basis without unreasonable efforts. This is due to the inherent difficulty in forecasting certain items that are necessary for such reconciliation, including (without limitation) non-cash stock-based compensation expense, integration-related expenses, restructuring and transformation-related costs, impairment charges, and the related tax effects of these items. These items are uncertain, depend on various factors outside of the Company's control, and could be material to the Company's results calculated in accordance with GAAP. Accordingly, the Company is unable to provide a probable significance of the unavailable information, but such unavailable information could have a potentially significant impact on the Company's actual net income for fiscal year 2026.

------

**Conference Call and Webcast**

Neogen Corporation will host a conference call today at 8:00 a.m. Eastern Time to discuss the Company's financial results. The live webcast of the conference call and accompanying presentation materials can be accessed through Neogen's website at neogen.com/investor-relations. For those unable to access the webcast, the conference call can be accessed by dialing 1-800-549-8228 (North America) or (+1) 646-564-2877 (International) and requesting the Neogen Corporation Third Quarter 2026 Earnings Call (conference ID 70064). A replay of the conference call and webcast will be available shortly following the conclusion of the call, and can be accessed domestically or internationally by dialing 1-888-660-6264 or (+1) 646-517-3975, respectively, and providing the entry code 70064#, or through Neogen's Investor Relations website at <u>neogen.com/investor-relations</u>.

**About Neogen** 

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

**Safe Harbor Statement**<br>This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding our outlook, guidance and objectives; plans and expectations relating to our manufacturing transitions (including Petrifilm), supply chain remediation, commercial initiatives and cost-efficiency programs; expected timing and effects of portfolio actions (including the announced divestiture of the genomics business); capital allocation and deleveraging goals; market conditions and demand trends; and any other statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "project," "should," "target," "will," and similar expressions, and their negatives.

These "forward-looking statements" are management's present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.

These risks include, but are not limited to risks relating to the integration of the 3M Food Safety business, risks related to potential tax benefits realized through the 3M transaction, risks related to tariffs and other trade measures, risks related to our international operations and expansion into new geographic markets, risks related to identified material weaknesses in our internal control over financial reporting, risks related to promoting internal growth and identifying and integrating acquisitions, risks related to failure of our systems infrastructure and security breaches of our information systems, risks related to disruption in our manufacturing and service operations, risks related to disruption of third-party package delivery services or pricing increases, risks related to dependence on key suppliers, risks related to the use of distributors for product sales, risks related to the development of new products and technologies, risks related to our ability to maintain a positive reputation, risks related to customer loss, risks related to increased raw material costs, risks related to anti-bribery, trade control, trade sanctions, and anti-corruption laws, risks related to changes in domestic and foreign laws and regulations, risks related to tax audits and changes in tax laws in different jurisdictions, risks related to deterioration in profitability, cash flow, and asset impairments, risks related to competition, risks related to agricultural marketplace, risks related to our substantial indebtedness, risks related to the outcomes of litigation and other legal proceedings, risks related to our ability to obtain and protect intellectual property, risks related to patent infringement challenges, risks related to governmental regulation, risks related to our ability to attract and retain key personnel, risks related to product or service liability claims, risks related to changing political conditions, risks related to climate change, risks related to our inability to meet stakeholder expectations around environmental, social, and governance objectives, risks related to tax legislation, and other factors discussed under the heading "Risk Factors" contained in Item 1A of the company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on July 30, 2025, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current

------

Reports on Form 8-K. Neogen is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

------

**Neogen Corporation**

**Condensed Consolidated Statements of Operations (unaudited)** 

*(in millions, except per share amounts)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended February 28,** | **Three months ended February 28,** | **Nine months ended February 28,** | **Nine months ended February 28,** |
|  | **2026** | **2025** | **2026** | **2025** |
| Revenues |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product revenues | $186.2 | $196.5 | $569.4 | $596.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Service revenues | 25.0 | 24.5 | 75.7 | 72.6 |
| Total Revenues | 211.2 | 221.0 | 645.1 | 669.2 |
| Cost of Revenues |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product revenues | 96.0 | 95.8 | 296.6 | 293.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of service revenues | 16.2 | 14.9 | 47.8 | 47.2 |
| Total Cost of Revenues | 112.2 | 110.7 | 344.4 | 340.7 |
| Gross Profit | 99.0 | 110.3 | 300.7 | 328.5 |
| Operating Expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 38.2 | 44.6 | 125.5 | 136.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 60.3 | 55.8 | 186.4 | 165.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill impairment |  |  |  | 461.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 3.8 | 4.5 | 13.5 | 14.8 |
| Total Operating Expenses | 102.3 | 104.9 | 325.4 | 778.3 |
| Operating Loss (Income) | (3.3) | 5.4 | (24.7) | (449.8) |
| Other (Expense) Income |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | (13.9) | (17.0) | (43.7) | (52.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of business |  |  | 76.4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | (3.1) | 1.9 | (4.9) | (0.1) |
| Total Other (Expense) Income | (17.0) | (15.1) | 27.8 | (52.1) |
| (Loss) Income Before Taxes | (20.3) | (9.7) | 3.1 | (501.9) |
| Income Tax (Benefit) Expense | (3.3) | 1.2 | (0.3) | (22.1) |
| Net (Loss) Income | $(17.0) | $(10.9) | $3.4 | $(479.8) |
| Net (Loss) Income Per Share |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.08) | $(0.05) | $0.02 | $(2.21) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.08) | $(0.05) | $0.02 | $(2.21) |
| Weighted Average Shares Outstanding |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 217.7 | 217.0 | 217.4 | 216.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 217.7 | 217.0 | 217.9 | 216.8 |

---

------

**Neogen Corporation** 

**Condensed Consolidated Balance Sheets (unaudited)**

*(in millions, except per share amounts)*

---

| | | |
|:---|:---|:---|
|  | **February 28, 2026** | **May 31, 2025** |
| <u>Assets</u> |  |  |
| Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $159.9 | $129.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance of $4.1 and $5.4 | 137.1 | 153.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net of reserves of $16.5 and $16.5 | 161.7 | 190.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 63.1 | 53.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assets held for sale | 68.2 | 50.4 |
| Total Current Assets | 590.0 | 576.9 |
| Net Property and Equipment | 331.9 | 339.1 |
| Other Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right of use assets | 15.7 | 17.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 1047.8 | 1064.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortizable intangible assets, net | 1341.8 | 1410.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets | 31.8 | 35.2 |
| Total Assets | $3359.0 | $3443.8 |
| <u>Liabilities and Stockholders' Equity</u> |  |  |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of debt | $— | $19.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 75.2 | 79.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | 23.5 | 14.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax payable | 9.9 | 5.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 3.5 | 11.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 3.9 | 5.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 28.2 | 32.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liabilities held for sale | 6.4 | 6.6 |
| Total Current Liabilities | 150.6 | 174.0 |
| Deferred Income Tax Liability | 269.2 | 280.9 |
| Non-current debt | 793.3 | 874.8 |
| Other non-current liabilities | 43.5 | 42.9 |
| Total Liabilities | 1256.6 | 1372.6 |
| Commitments and Contingencies |  |  |
| Equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $1.00 par value, 0.1 shares authorized, none issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.16 par value, 315.0 shares authorized, 217.7 and 217.0 shares issued and outstanding | 34.8 | 34.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 2613.1 | 2601.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (12.5) | (28.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (533.0) | (536.4) |
| Total Stockholders' Equity | 2102.4 | 2071.2 |
| Total Liabilities and Stockholders' Equity | $3359.0 | $3443.8 |

---

------

**Neogen Corporation** 

**Condensed Consolidated Statements of Cash Flows (unaudited)** 

*(in millions)* 

---

| | | |
|:---|:---|:---|
|  | **Nine months ended February 28,** | **Nine months ended February 28,** |
|  | **2026** | **2025** |
| Cash Flows provided by Operating Activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $3.4 | $(479.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 86.9 | 89.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (15.5) | (33.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 10.4 | 13.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on disposal of property and equipment | 1.2 | 0.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs | 1.5 | 2.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill and Other asset impairment |  | 470.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on refinancing and extinguishment of debt | 0.4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of business | (76.4) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (0.2) | (0.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 16.6 | 9.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 21.5 | (25.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (10.0) | (6.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 20.5 | 6.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense accrual | (7.6) | (7.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in other non-current assets and non-current liabilities | 0.3 | 3.2 |
| Net Cash provided by Operating Activities | 53.0 | 41.8 |
| Cash Flows provided by (used for) Investing Activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, equipment and intangible assets | (47.3) | (88.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the maturities of marketable securities |  | 0.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of business, net of cash divested | 121.7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the sale of property and equipment and other | 0.1 | 4.9 |
| Net Cash provided by (used for) Investing Activities | 74.5 | (83.3) |
| Cash Flows (used for) provided by Financing Activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of shares related to equity compensation and employee stock purchase plan | 1.7 | 2.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax payments related to share-based awards | (0.7) | (1.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of finance lease | (0.1) | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of outstanding debt | (100.0) |  |
| Net Cash (used for) provided by Financing Activities | (99.1) | 0.5 |
| Effects of Foreign Exchange Rate on Cash | 2.5 | (1.9) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 30.9 | (42.9) |
| Cash and Cash Equivalents, Beginning of Year | 129.0 | 170.6 |
| Cash and Cash Equivalents, End of Year | $159.9 | $127.7 |
| **Supplemental cash flow information** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment obtained for noncash consideration | $— | $0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Right of use assets obtained in exchange for new operating lease liabilities | $4.4 | $7.0 |

---

------

**Statement regarding use of non-GAAP financial measures**

<br>This press release includes certain non-GAAP financial measures, which management believes are useful to investors, securities analysts and other interested parties. Management uses Adjusted EBITDA as a key profitability measure. This is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses. Adjusted EBITDA Margin is Adjusted EBITDA for a particular period expressed as a percentage of revenues for that period.

Management uses Adjusted Gross Profit as an additional measure of profitability. Adjusted Gross Profit is a non-GAAP measure that represents net income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.

Management uses Adjusted Operating Income as an additional measure of profitability. Adjusted Operating Income is a non-GAAP measure that represents operating income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.

Management uses Adjusted Net Income as an additional measure of profitability. Adjusted Net Income is a non-GAAP measure that represents net income before certain items that impact comparison of the performance of our business, either period-over-period or with other businesses.

Core revenue growth is a non-GAAP measure that represents net sales for the period excluding the effects of foreign currency translation rates and the impacts of acquisitions and discontinued product lines, where applicable. Core revenue growth is presented to allow for a meaningful comparison of year-over-year performance without the volatility caused by foreign currency translation rates, or the incomparability that would be caused by the impact of an acquisition, disposal or product line discontinuation.

These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP. Please see below for a reconciliation of historical non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with GAAP.

------

**NEOGEN CORPORATION** 

**RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED EBITDA (UNAUDITED)**

(i*n millions*)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended February 28,** | **Three months ended February 28,** | **Nine months ended February 28,** | **Nine months ended February 28,** |
|  | **2026** | **2025** | **2026** | **2025** |
| **Net (Loss) Income** | $**(17.0)** | $**(10.9)** | $**3.4** | $**(479.8)** |
| Income tax (benefit) expense | $(3.3) | $1.2 | $(0.3) | (22.1) |
| Depreciation and amortization | 28.9 | 29.4 | 86.9 | 89.2 |
| Interest expense, net | 13.9 | 17.0 | 43.7 | 52.0 |
| **EBITDA** | $**22.5** | $**36.7** | $**133.7** | $**(360.7)** |
| Share-based compensation | 1.1 | 4.2 | 10.4 | 13.0 |
| FX transaction loss (gain) on loan and other revaluation <sup>(1)</sup> | 1.9 | (0.3) | 2.1 | (0.2) |
| Transaction costs <sup>(2)</sup> | 3.7 | 0.5 | 8.9 | 1.6 |
| 3M integration costs <sup>(3)</sup> | 0.4 | 0.6 | 1.1 | 5.4 |
| Sample collection transition and ramp up costs <sup>(4)</sup> | 4.6 | 2.9 | 13.4 | 4.7 |
| Petrifilm duplicate manufacturing costs <sup>(5)</sup> | 4.1 | 0.7 | 9.8 | 0.8 |
| Transformation initiatives and related costs <sup>(6)</sup> | 5.3 | 2.5 | 16.2 | 3.3 |
| Restructuring <sup>(7)</sup> | 0.4 | 0.2 | 6.9 | 10.1 |
| Goodwill impairment |  |  |  | 461.4 |
| Contingent consideration adjustments | 0.9 | 0.5 | 0.9 | 0.5 |
| ERP expense <sup>(8)</sup> | 0.6 | 0.6 | 1.7 | 3.2 |
| Gain on sale of business |  |  | (76.4) |  |
| Other | 2.7 | (0.5) | 3.7 | 0.5 |
| **Adjusted EBITDA** | $**48.2** | $**48.6** | $**132.4** | $**143.6** |
| Adjusted EBITDA margin (% of sales) | 22.8% | 22.0% | 20.5% | 21.5% |

---

(1)Net foreign currency transaction loss (gain) associated with the revaluation of foreign-currency-denominated intercompany loans.

(2)Includes legal, accounting, tax, consulting and other related costs to execute corporate transactions and capital structure initiatives.

(3)Includes costs associated with 3M transition agreements and related integration costs.

(4)Includes costs associated with transitioning off the 3M transition contract manufacturing agreement and ramp-up costs associated with our sample collection product line.

(5)Duplicate costs associated with the startup of Petrifilm manufacturing.

(6)Includes consulting and other costs, including severance, associated with transformation initiatives.

(7)Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global headcount and global genomics business.

(8)Expenses related to ERP implementation.

------

**NEOGEN CORPORATION** 

**RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED NET INCOME (UNAUDITED)**

(i*n millions*)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended February 28,** | **Three months ended February 28,** | **Nine months ended February 28,** | **Nine months ended February 28,** |
|  | **2026** | **2025** | **2026** | **2025** |
| **Net (Loss) Income** | $**(17.0)** | $**(10.9)** | $**3.4** | $**(479.8)** |
| Amortization of acquisition-related intangibles | 22.0 | 22.9 | 66.9 | 69.2 |
| Share-based compensation | 1.1 | 4.2 | 10.4 | 13.0 |
| FX transaction loss (gain) on loan and other revaluation <sup>(1)</sup> | 1.9 | (0.3) | 2.1 | (0.2) |
| Transaction costs <sup>(2)</sup> | 3.7 | 0.5 | 8.9 | 1.6 |
| 3M integration costs <sup>(3)</sup> | 0.4 | 0.6 | 1.1 | 5.4 |
| Sample collection transition and ramp up costs <sup>(4)</sup> | 4.6 | 2.9 | 13.4 | 4.7 |
| Petrifilm duplicate manufacturing costs <sup>(5)</sup> | 4.1 | 0.7 | 9.8 | 0.8 |
| Transformation initiatives and related costs <sup>(6)</sup> | 5.3 | 2.5 | 16.2 | 3.3 |
| Restructuring <sup>(7)</sup> | 0.4 | 0.2 | 6.9 | 10.1 |
| Goodwill impairment |  |  | - | 461.4 |
| Contingent consideration adjustments | 0.9 | 0.5 | 0.9 | 0.5 |
| ERP expense <sup>(8)</sup> | 0.6 | 0.6 | 1.7 | 3.2 |
| Gain on sale of business |  |  | (76.4) |  |
| Other | 2.7 | (0.5) | 3.7 | 0.5 |
| Estimated tax effect of above adjustments <sup>(9)</sup> | (11.3) | (3.0) | (17.5) | (34.1) |
| **Adjusted Net Income** | **19.4** | $**20.9** | $**51.5** | **59.6** |
| **Adjusted Earnings Per Share** | $**0.09** | $**0.10** | $**0.24** | $**0.27** |

---

(1)Net foreign currency transaction loss (gain) associated with the revaluation of foreign-currency-denominated intercompany loans.

(2)Includes legal, accounting, tax, consulting and other related costs to execute corporate transactions and capital structure initiatives.

(3)Includes costs associated with 3M transition agreements and related integration costs.

(4)Includes costs associated with transitioning off the 3M transition contract manufacturing agreement and ramp-up costs associated with our sample collection product line.

(5)Duplicate costs associated with the startup of Petrifilm manufacturing.

(6)Includes consulting and other costs, including severance, associated with transformation initiatives.

(7)Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global headcount and global genomics business.

(8)Expenses related to ERP implementation.

(9)Tax effect of adjustments is calculated using projected effective tax rates for each applicable item.

------

**NEOGEN CORPORATION** 

**RECONCILIATION OF GROSS PROFIT TO ADJUSTED GROSS PROFIT (UNAUDITED)**

(i*n millions*)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended February 28,** | **Three months ended February 28,** | **Nine months ended February 28,** | **Nine months ended February 28,** |
|  | **2026** | **2025** | **2026** | **2025** |
| **Gross Profit** | $**99.0** | $**110.3** | $**300.7** | $**328.5** |
| Transaction costs <sup>(1)</sup> | 0.5 |  | 0.5 |  |
| 3M integration costs <sup>(2)</sup> | 0.4 | 0.6 | 1.1 | 5.4 |
| Sample collection transition and ramp up costs <sup>(3)</sup> | 4.6 | 2.9 | 13.4 | 4.7 |
| Petrifilm duplicate manufacturing costs <sup>(4)</sup> | 4.1 | 0.7 | 9.8 | 0.8 |
| Restructuring <sup>(5)</sup> |  | (0.3) |  | 4.6 |
| Other | 0.6 | (0.7) | 0.4 | 0.7 |
| **Adjusted Gross Profit** | $**109.2** | $**113.5** | $**325.9** | $**344.7** |

---

(1)Includes certain manufacturing costs to execute corporate transactions.

(2)Includes costs associated with 3M transition agreements and related integration costs.

(3)Includes costs associated with transitioning off the 3M transition contract manufacturing agreement and ramp-up costs associated with our sample collection product line.

(4)Duplicate costs associated with the startup of Petrifilm manufacturing.

(5)Non-cash impairment and other related exit costs primarily associated with a reduction in our global genomics business.

------

**NEOGEN CORPORATION** 

**RECONCILIATION OF OPERATING (LOSS) INCOME TO ADJUSTED OPERATING INCOME (UNAUDITED)**

(i*n millions*)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended February 28,** | **Three months ended February 28,** | **Nine months ended February 28,** | **Nine months ended February 28,** |
|  | **2026** | **2025** | **2026** | **2025** |
| **Operating (Loss) Income** | $**(3.3)** | $**5.4** | $**(24.7)** | $**(449.8)** |
| Amortization of acquisition-related intangibles | 22.0 | 22.9 | 66.9 | 69.2 |
| Share-based compensation | 1.1 | 4.2 | 10.4 | 13.0 |
| Transaction costs <sup>(1)</sup> | 3.7 | 0.5 | 8.3 | 1.6 |
| 3M Integration costs <sup>(2)</sup> | 0.4 | 0.6 | 1.1 | 5.4 |
| Sample collection transition and ramp up costs <sup>(3)</sup> | 4.6 | 2.9 | 13.4 | 4.7 |
| Petrifilm duplicate manufacturing costs <sup>(4)</sup> | 4.1 | 0.7 | 9.8 | 0.8 |
| Transformation initiatives and related costs <sup>(5)</sup> | 5.3 | 2.5 | 16.2 | 3.3 |
| Restructuring <sup>(6)</sup> | 0.4 | 0.2 | 6.9 | 10.1 |
| Goodwill impairment |  |  |  | 461.4 |
| ERP expense <sup>(7)</sup> | 0.6 | 0.6 | 1.7 | 3.2 |
| Other | 3.3 | 2.1 | 4.8 | 3.2 |
| **Adjusted Operating Income** | $**42.2** | $**42.6** | $**114.8** | $**126.1** |

---

(1)Includes legal, accounting, tax, consulting and other related costs to execute corporate transactions and capital structure initiatives.

(2)Includes costs associated with 3M transition agreements and related integration costs.

(3)Includes costs associated with transitioning off the 3M transition contract manufacturing agreement and ramp-up costs associated with our sample collection product line.

(4)Duplicate costs associated with the startup of Petrifilm manufacturing.

(5)Includes consulting and other costs, including severance, associated with transformation initiatives.

(6)Severance, non-cash impairment, and other related exit costs primarily associated with a reduction in our global headcount and global genomics business.

(7)Expenses related to ERP implementation.

------

**NEOGEN CORPORATION** 

**RECONCILIATION OF GROWTH TO CORE GROWTH**

(*In millions*)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Q3 FY26** | **Q3 FY25** | **Growth** | **Foreign Currency** | **Acquisitions / Divestitures** | **Core Revenue Growth** |
| Food Safety | $156.7 | $152.8 | 2.6% | 4.0% | (5.4%) | 4.0% |
| Animal Safety | $54.5 | $68.2 | (20.1%) | 0.5% | (11.9%) | (8.7%) |
| **Total Neogen** | $**211.2** | $**221.0** | **(4.4**<br>**%)** | **3.0%** | **(7.5**<br>**%)** | **0.1%** |

---

Source: Neogen Corporation

**Investor Contact** 

Scott Gleason

(435) 395-0254

sgleason@neogen.com

**Media Contact:** <br>Lauren White <br>(202) 320-8677<br><u>lwhite@neogen.com</u>

------